Loading stock data…
Fulgent Genetics (FLGT)
$20.53+0.57 (+2.86%)
Market ClosedLast close Jun 29
Fulgent Genetics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fulgent Genetics, Inc. in the Healthcare sector is trading at $20.53 with a market capitalization of $511M. Wall Street consensus targets $18.50 (2 analysts), implying a -9.9% move over the next 12 months. The stock is currently 34% below its 52-week high of $31.04, remaining 5.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -9.9% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $71.14M↓ | $83.34M↓ | $84.07M↑ | $81.80M↑ | $73.46M |
| Gross Profit | $21.49M↓ | $32.58M↓ | $35.51M↑ | $34.44M↑ | $28.35M |
| Operating Income | -$34.62M↑ | -$36.24M↓ | -$15.35M↑ | -$19.71M↑ | -$19.80M |
| Net Income | -$24.83M↓ | -$23.42M↓ | -$6.61M↑ | -$18.96M↓ | -$11.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$510.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.03%
Volume
Today's trading volume
292,396
Recent News
Fulgent Genetics (FLGT) Stock Faces Mixed Analyst Target Changes After Margin Questions
The latest price target update for Fulgent Genetics keeps the model fair value at US$15.00, signaling that analysts are not making a major shift to the core valuation framework. Instead, the change reflects fresh commentary on how the current share price lines up with updated expectations around execution risk and what investors are prepared to pay for future earnings. As you read on, you will see how this evolving narrative fits with recent guidance, clinical news, and what it may mean for...
How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent Developments
Fulgent Genetics enters this update cycle with no changes to its price targets, leaving the existing analyst expectations intact for now. Even without new signals on where analysts think the stock could head next, you can still track what this steady stance might mean for your own view of the company. Read on to see how to keep up with the evolving narrative around Fulgent Genetics and where to look as fresh information comes through. Stay updated as the Fair Value for Fulgent Genetics shifts...
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Despite a dip in revenue, Fulgent Genetics Inc (FLGT) focuses on strategic acquisitions and pipeline advancements to bolster future growth.
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Fulgent Genetics, Inc.'s Q1 2026 earnings call
Fulgent Genetics Q1 Earnings Call Highlights
Fulgent Genetics (NASDAQ:FLGT) reported first-quarter 2026 revenue of $71.1 million as the company worked through a planned decline in testing volumes from its largest customer while integrating the recently completed acquisitions of Bako Diagnostics and StrataDX. First-quarter revenue pressured by